• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Orexigen(R) Therapeutics Announces Contrave(R) Data Presentations at Annual Scientific Meeting of The Obesity Society

Posted on: Wednesday, 21 October 2009, 07:01 CDT

SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone SR/bupropion SR) data presentations at the 27th Annual Scientific Meeting of The Obesity Society. The meeting will be held at the Marriott Wardman Park Hotel in Washington, D.C., October 24 - 28, 2009.

Saturday, October 24: Pre-Conference Panel Discussion Presenter: Dennis Kim, M.D., Senior Vice President, Medical Affairs Orexigen Therapeutics Topic: Pharmacotherapy Update Time: 1:00 - 3:45 pm ET Location: Marriott Ballroom Salon 3 Sunday, October 25: Poster Presentations Embargo Lifts October 25 at 1:00 p.m. ET Posters Available 1-2pm. and 5-7pm ET Abstract: 220-P Presenter: Cheryl Rock, PhD, University of California La Jolla, San Diego, CA Title: "Naltrexone SR/Bupropion SR Combination Therapy Reduced Body Weight and Improved Metabolic Risk Factors" Location: Marriott Exhibit Hall Abstract: 218-P Presenter: James Hill, PhD, University of Colorado, Denver, CO Title: "Naltrexone SR/Bupropion SR - Induced Weight Loss is Independent of Nausea" Location: Marriott Exhibit Hall Abstract: 216-P Presenter: Patrick O'Neil, PhD, Medical University of South Carolina, Charleston, S.C. Title: "Early Weight Loss with Naltrexone SR/Bupropion SR Combination Therapy for Obesity Predicts Long-term Weight Loss" Location: Marriott Exhibit Hall Tuesday, October 27: Late-Breaker Presentations Embargo Lifts October 27 at 11:00 a.m. ET Presenter: Frank Greenway, M.D., Pennington Biomedical Research Center, Baton Rouge, LA Title: "COR-I: A Phase 3 Study Evaluating Two Doses of Naltrexone SR/Bupropion SR Combination Therapy Showed Significant and Sustained Weight Loss in Overweight and Obese Subjects" Time: 11:00 -11:20 a.m. ET Location: Marriott Ballroom Salon 2 Embargo Lifts October 27 at 11:20 a.m. ET Presenter: Caroline Apovian, M.D. Boston University Medical Center, Boston, MA Title: "Results of the Phase 3, 56-week, COR II Study: Naltrexone SR/Bupropion SR Combination Therapy Led to Significant and Sustained Weight Loss in Overweight and Obese Subjects" Time: 11:20 -11:40 a.m. ET Location: Marriott Ballroom Salon 2

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave®, has completed the COR clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM), has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Source: PR Newswire

More News in this Category